This Top Big Pharma Stock Just Got an Upgrade

Each week, we like to take a moment to boil down the biggest news from the most influential companies in the pharmaceuticals industry, and tell our viewers what that news means for you. We call that segment our Big Pharma Roundup.

In this week's installment, diabetes titan Novo Nordisk (NYSE: NVO  ) just received a credit rating upgrade from Moody's; already at Aa2, the company has been elevated to Aa1, which is only one grade away from Moody's ultimate Aaa rating. Motley Fool health care analyst Brenton Flynn highlights some of the new drugs that will contribute to NVO's solid growth.

While Novo Nordisk is the premier diabetes player, there's more than one way to play the trend. Still down around 90% from its highs less than a decade ago, there's been no giant leap for MannKind shareholders. The debate rages over whether the company's revolutionary inhalable insulin, slated to go in front of the FDA next year, will be a complete flop or a massive blockbuster success. In this brand new premium report on MannKind, we outline every key topic investors have to know with this risky stock. It also comes with a full year of analyst updates to keep you covered as key news develops, so don't miss out — simply click here now to claim your copy today.


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 10, 2012, at 5:23 PM, WCoastGuynCA wrote:

    Mannkind is expected to announce on 12/20 that the number of authorized shares will be increased from 350,000,000 to 550,000,000.

    This news combined with end of the year tax-loss selling could drop the share price back to the $1.70 range.

    Anyone considering investing in the company may want to wait until next year to buy shares.

Add your comment.

DocumentId: 2144834, ~/Articles/ArticleHandler.aspx, 7/24/2014 4:27:45 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement